Biotech Values

[DewDiligence]

CBLI—(+41%/AH)—reverse-merges into Cytocom Inc:

https://finance.yahoo.com/news/cytocom-cleveland-biolabs-announce-definitive-200500691.html

Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis… Specifically, Cytocom has four programs in late-stage clinical development in Crohn's disease, Fibromyalgia, Multiple Sclerosis and Pancreatic Cancer.

The PR doesn’t say what the equity split will be, but it does say that Cytocom shareholders will end up with a majority stake.

CC Tuesday at 8am ET.